A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial
2017 ◽
Vol 88
(5)
◽
pp. e1.63-e1
◽
Keyword(s):
Phase 3
◽
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS4132-TPS4132
◽